FilingSEC EDGAR8-K
Biofrontera Receives FDA Approval For Ameluz In Superficial Basal Cell Carcinoma
· SEC accepted
StageFDA Approval
Filing content
The FDA approved the supplemental New Drug Application for Ameluz in combination with the BF-RhodoLED lamp for the treatment of superficial basal cell carcinoma in adults.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…